RhumbLine Advisers
UTMD icon

RhumbLine Advisers’s Utah Medical Products UTMD Stock Holding History

RhumbLine Advisers’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Sell
3,999
-176
-4% -$11.1K ﹤0.01% 3020
2025
Q4 		$234K Sell
4,175
-844
-17% -$48.9K ﹤0.01% 3105
2025
Q3 		$316K Sell
5,019
-697
-12% -$41.2K ﹤0.01% 2960
2025
Q2 		$325K Buy
5,716
+550
+11% +$29.9K ﹤0.01% 2937
2025
Q1 		$289K Sell
5,166
-829
-14% -$49.7K ﹤0.01% 2909
2024
Q4 		$369K Sell
5,995
-650
-10% -$42K ﹤0.01% 2857
2024
Q3 		$445K Buy
6,645
+1,137
+21% +$77.2K ﹤0.01% 2775
2024
Q2 		$368K Buy
5,508
+812
+17% +$55.3K ﹤0.01% 2874
2024
Q1 		$334K Buy
4,696
+158
+3% +$11.9K ﹤0.01% 2924
2023
Q4 		$382K Sell
4,538
-85
-2% -$7.05K ﹤0.01% 2821
2023
Q3 		$398K Buy
4,623
+124
+3% +$11.4K ﹤0.01% 2745
2023
Q2 		$419K Sell
4,499
-84
-2% -$7.92K ﹤0.01% 2806
2023
Q1 		$434K Buy
4,583
+82
+2% +$7.54K ﹤0.01% 2488
2022
Q4 		$452K Buy
4,501
+112
+3% +$10.2K ﹤0.01% 2514
2022
Q3 		$374K Buy
4,389
+275
+7% +$24.3K ﹤0.01% 2631
2022
Q2 		$353K Sell
4,114
-487
-11% -$41.5K ﹤0.01% 2671
2022
Q1 		$413K Sell
4,601
-393
-8% -$36.1K ﹤0.01% 2505
2021
Q4 		$499K Sell
4,994
-52
-1% -$5.31K ﹤0.01% 2511
2021
Q3 		$468K Buy
5,046
+175
+4% +$15.5K ﹤0.01% 2577
2021
Q2 		$414K Buy
4,871
+411
+9% +$35.6K ﹤0.01% 2649
2021
Q1 		$386K Sell
4,460
-150
-3% -$13.2K ﹤0.01% 2605
2020
Q4 		$389K Buy
4,610
+351
+8% +$29.9K ﹤0.01% 2548
2020
Q3 		$340K Sell
4,259
-624
-13% -$51.8K ﹤0.01% 2459
2020
Q2 		$433K Buy
4,883
+115
+2% +$10.3K ﹤0.01% 2415
2020
Q1 		$448K Hold
4,768
– – ﹤0.01% 2214
2019
Q4 		$514K Buy
4,768
+35
+0.7% +$3.55K ﹤0.01% 2347
2019
Q3 		$454K Buy
4,733
+68
+1% +$6.32K ﹤0.01% 2365
2019
Q2 		$446K Sell
4,665
-7
-0.1% -$589 ﹤0.01% 2401
2019
Q1 		$412K Buy
4,672
+31
+0.7% +$2.73K ﹤0.01% 2407
2018
Q4 		$386K Buy
4,641
+1,576
+51% +$139K ﹤0.01% 2417
2018
Q3 		$289K Sell
3,065
-200
-6% -$19.1K ﹤0.01% 2536
2018
Q2 		$360K Buy
3,265
+136
+4% +$14.2K ﹤0.01% 2453
2018
Q1 		$309K Sell
3,129
-80
-2% -$7.14K ﹤0.01% 2420
2017
Q4 		$261K Sell
3,209
-602
-16% -$47K ﹤0.01% 2523
2017
Q3 		$280K Sell
3,811
-70
-2% -$5.03K ﹤0.01% 2586
2017
Q2 		$281K Sell
3,881
-425
-10% -$28K ﹤0.01% 2592
2017
Q1 		$268K Buy
4,306
+157
+4% +$9.88K ﹤0.01% 2561
2016
Q4 		$302K Sell
4,149
-546
-12% -$35.5K ﹤0.01% 2489
2016
Q3 		$281K Buy
4,695
+100
+2% +$6.36K ﹤0.01% 2520
2016
Q2 		$289K Buy
4,595
+621
+16% +$40.1K ﹤0.01% 2555
2016
Q1 		$249K Buy
3,974
+125
+3% +$7.37K ﹤0.01% 2625
2015
Q4 		$225K Buy
+3,849
New +$218K ﹤0.01% 2738
2015
Q3 		– Sell
-3,470
Closed -$207K – 3020
2015
Q2 		$207K Sell
3,470
-200
-5% -$11.3K ﹤0.01% 2874
2015
Q1 		$220K Buy
+3,670
New +$216K ﹤0.01% 2781

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's UTMD Position: Q1 2026 in Review

RhumbLine Advisers reduced its Utah Medical Products (UTMD) stake by 4.2% in Q1 2026, selling an estimated $11.1K and leaving 3,999 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

RhumbLine Advisers first reported a position in UTMD in Q1 2015 and has held it in 44 quarters since. The position peaked at $514K in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • RhumbLine Advisers held 3,999 shares of Utah Medical Products worth $248K as of Q1 2026.
  • RhumbLine Advisers sold 176 Utah Medical Products shares in Q1 2026, an estimated $11.1K.
  • Utah Medical Products made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3020 holding.
  • RhumbLine Advisers first reported a position in Utah Medical Products in Q1 2015 and has held it in 44 quarters since.
  • RhumbLine Advisers's Utah Medical Products position peaked at $514K in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.